Clipperton acted as the exclusive advisor to Inova and its shareholders. Carlyle’s and NextStage’s investment will enable Inova to accelerate its growth, fund product innovation and M&A initiatives.
Trusted by the largest and most innovative life science companies globally, Inova’s SaaS platform is uniquely positioned between large pharmaceutical companies and biotechs to accelerate and foster successful collaboration on life science innovation and R&D. Its advanced specialized product suite offers biopharma companies with the perfect tools to source, qualify and manage licensing and collaborations.
This transaction highlights Clipperton’s sector expertise in both SaaS, following deals such as innosabi (sold to Questel), Sendinblue ($160m round with Bridgepoint, BlackRock and Bpifrance) and Lengow (received a growth investment from Marlin Equity Partners), and Healthtech, following deals such as Withings ($60m round with Gilde Healthcare, Idinvest Partners and Bpifrance), and Endospan ($25m round led by Cryolife).
July 1st, 2021 - Clipperton acted as the exclusive advisor to Inova and its shareholders on Carlyle's [NASDAQ: CG] and NextStage's $70 million growth investment to further accelerate growth, fund product innovation and support M&A initiatives. Carlyle will become Inova’s largest shareholder under the deal, while Management and historic investor NextStage AM have reaffirmed their strong commitment.
